



31 January 2017
EMA/HMPC/359238/2016
Committee on Herbal Medicinal Products (HMPC)

European Union herbal monograph on *Olea europaea* L., folium

Final

Initial assessment	
Discussion in Working Party on European Union monographs and list (MLWP)	November 2009 January 2010 March 2010 September 2010 January 2011
Adoption by Committee on Herbal Medicinal Products (HMPC) for release for consultation	27 January 2011
End of consultation (deadline for comments)	15 August 2011
Re-discussion in MLWP	September 2011
Adoption by HMPC Monograph (EMA/HMPC/430507/2009) Assessment Report (EMA/HMPC/430506/2009) List of references (EMA/HMPC/430505/2009) Overview of comments (EMA/HMPC/736741/2011)	22 November 2011
First systematic review	
Discussion in Working Party on European Union monographs and list (MLWP)	May/June 2016 July 2016 September 2016 November 2016
Adoption by HMPC	31 January 2017
Keywords	Herbal medicinal products; HMPC; European Union herbal monographs; traditional use; <i>Olea europaea</i> L., folium; Oleae folium; olive leaf



BG (bulgarski): Маслина, лист	LT (lietuvių kalba): Alyvmedžių lapai
CS (čeština): olivovníkový list	LV (latviešu valoda): Olīvu lapas
DA (dansk): Olivenblad	MT (Malti): werqa taż-żebbuġa
DE (Deutsch): Ölbaumblätter	NL (Nederlands): Olijfblad
EL (elliniká): φύλλο ελαιάς	PL (Poland): Liść oliwki
EN (English): olive leaf	PT (português): oliveira, folha
ES (español): olivo, hoja de	RO (română): frunză de măslin
ET (eesti keel): õlipuu leht	SK (slovenčina): list olivy
FI (suomi): oliivipuu, lehti	SL (slovenščina): list divje oljke
FR (français): olivier (feuille d')	SV (svenska): olivträd, blad
HR (hrvatski): maslinov list	<i>IS (islenska):</i>
HU (magyar): olajfa levél	<i>NO (norsk): olivenblad</i>
IT (italiano): Olivo foglia	

European Union herbal monograph on *Olea europaea* L., folium

1. Name of the medicinal product

To be specified for the individual finished product.

2. Qualitative and quantitative composition^{1,2}

Well-established use	Traditional use
	With regard to the registration application of Article 16d(1) of Directive 2001/83/EC <i>Olea europaea</i> L., folium (olive leaf) i) Herbal substance Fresh or dried leaves ii) Herbal preparations a) Comminuted dried leaves b) Powdered dried leaves

3. Pharmaceutical form

Well-established use	Traditional use
	Herbal substance or comminuted herbal substance as herbal tea for oral use. Powdered dried leaves in solid dosage forms for oral use. The pharmaceutical form should be described by the European Pharmacopoeia full standard term.

4. Clinical particulars

4.1. Therapeutic indications

Well-established use	Traditional use
	Traditional herbal medicinal product used to promote the renal elimination of water, in mild cases of water retention after serious conditions have been excluded by a medical doctor. The product is a traditional herbal medicinal

¹ The material complies with the Ph. Eur. monograph (ref.: 1878).

² The declaration of the active substance(s) for an individual finished product should be in accordance with relevant herbal quality guidance.

Well-established use	Traditional use
	product for use in specified indication exclusively based upon long-standing use.

4.2. Posology and method of administration³

Well-established use	Traditional use
	<p>Posology</p> <p><i>Adults and elderly</i></p> <p>i) Herbal substance</p> <p>Herbal tea: 10 g of fresh leaves or 5 g of dried leaves in 150 ml of water as a decoction 2 times daily (morning and evening)</p> <p>Decoction time: allow to simmer to reach 100 ml of decoction.</p> <p>i) Herbal substance and ii) herbal preparation</p> <p>Dried leaves or a) comminuted dried leaves for infusion:</p> <p>Single dose: 6–10 g up to 3 times daily.</p> <p>Daily dose: 6–30 g</p> <p>ii) Herbal preparation</p> <p>b) Powdered dried leaves:</p> <p>Single dose: 275 mg 3-5 times daily or 210–400 mg 3 times daily.</p> <p>Daily dose: 630–1375 mg.</p> <p>The use in children and adolescents under 18 years of age is not recommended (see section 4.4 'Special warnings and precautions for use').</p> <p>Duration of use</p> <p>The herbal substance is traditionally used over a period of 2-4 weeks.</p> <p>If the symptoms persist longer than one week during the use of the medicinal product, a doctor or a qualified health care practitioner should be consulted.</p> <p>Method of administration</p> <p>Oral use</p>

³ For guidance on herbal substance/herbal preparation administered as herbal tea or as infusion/decoction/macerate preparation, please refer to the HMPC 'Glossary on herbal teas' (EMA/HMPC/5829/2010 Rev. 1).

4.3. Contraindications

Well-established use	Traditional use
	Hypersensitivity to the active substance. <u>Herbal substance and herbal preparation a)</u> Conditions where a reduced fluid intake is recommended (e.g. severe cardiac or renal disease).

4.4. Special warnings and precautions for use

Well-established use	Traditional use
	Patients with cardiac disease or renal impairment should seek medical advice before taking Olea medication. The use in children and adolescents under 18 years of age has not been established due to lack of adequate data. If symptoms worsen during the use of the medicinal product, a medical doctor or a qualified health care practitioner should be consulted.

4.5. Interactions with other medicinal products and other forms of interaction

Well-established use	Traditional use
	None reported

4.6. Fertility, pregnancy and lactation

Well-established use	Traditional use
	Safety during pregnancy and lactation has not been established. In the absence of sufficient data, the use during pregnancy and lactation is not recommended. No fertility data available.

4.7. Effects on ability to drive and use machines

Well-established use	Traditional use
	No studies on the effect on the ability to drive and use machines have been performed.

4.8. Undesirable effects

Well-established use	Traditional use
	None known. If adverse reactions occur, a doctor or a qualified health care practitioner should be consulted.

4.9. Overdose

Well-established use	Traditional use
	No case of overdose has been reported.

5. Pharmacological properties

5.1. Pharmacodynamic properties

Well-established use	Traditional use
	Not required as per Article 16c(1)(a)(iii) of Directive 2001/83/EC.

5.2. Pharmacokinetic properties

Well-established use	Traditional use
	Not required as per Article 16c(1)(a)(iii) of Directive 2001/83/EC.

5.3. Preclinical safety data

Well-established use	Traditional use
	Not required as per Article 16c(1)(a)(iii) of Directive 2001/83/EC, unless necessary for the safe use of the product. Tests on reproductive toxicity, and carcinogenicity have not been performed. Adequate data on genotoxicity have not been performed.

6. Pharmaceutical particulars

Well-established use	Traditional use
	Not applicable

7. Date of compilation/last revision

31 January 2017